

Merchant & Gould

An Intellectual Property Law Firm

**RECEIVED
CENTRAL FAX CENTER**

JAN 26 2005

3200 IDS Center
80 South Eighth Street
Minneapolis, Minnesota
55402-2215 USA
TEL 612.332.5300
FAX 612.332.9081
www.merchant-
gould.com

A Professional Corporation

Fax Transmission | January 26, 2005TO: Commissioner for Patents
Attn: Examiner Ungar, Susan Nmn
P.O. Box 1450
Alexandria, VA 22313-1450

FROM: John J. Gresens


OUR REF: 07885.0055USWO
TELEPHONE: 612.371.5265Total pages, including cover letter: 10PTO FAX NUMBER 1-703.872.9306

If you do NOT receive all of the pages, please telephone us at 612.371.5265, or fax us at 612.332.9081.

Title of Document Transmitted:

COMMUNICATION REGARDING FORM
1449Applicant: FODSTAD
Serial No.: 09/125,751
Filed: October 30, 1998
Group Art Unit: 1642
Our Ref. No.: 07885.0055USWO
Confirmation No. 8143

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: 
Name: John J. Gresens
Reg. No.: 33/112

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Antonette Peters
Signature01/26/05
Date

S/N 09/125,751

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: SATO et al. Examiner: Ungar, Susan Nmm
Serial No.: 09/125,751 Group Art Unit: 1642
Filed: October 30, 1998 Docket No.: 07885.0055USWO
Title: METHOD OF KILLING TARGET CELLS IN HARVESTED CELL
POPULATIONS WITH ONE OR MORE IMMUNOTOXINS

RECEIVED
CENTRAL FAX CENTER

JAN 26 2005

CERTIFICATE UNDER 37 CFR 1.8(b)

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on January 25, 2005.

By: Antonic Peters

Name: Antonic Peters

COMMUNICATION REGARDING FORM 1449

Ungar, Susan Nmm
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Ms. Ungar:

Pertaining to the above-referenced patent application, Applicants respectfully assert that on October 20, 1998, October 30, 1998, December 3, 1998, October 12, 1999 and October 5, 2004, Information Disclosure Statements were filed with the United States Patent and Trademark Office. However, the Forms 1449 have not been returned to the undersigned as being considered by the Examiner. Pursuant to the provisions of M.P.E.P. 609, it is requested that the attached Form 1449, marked as being considered and initialed by the Examiner, be returned to the undersigned with an official communication.

Respectfully submitted,

23552

PATENT TRADEMARK OFFICE

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Dated: January 25, 2005

JJG/acp

By: John J. Gresens

John J. Gresens
Reg. No. 33,112

Date Mailed: October 20, 1998

Sheet 1 of 1

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885,55USWO	Application Number: 09/125,751
	Applicant: FODSTAD et al.	
	Filing Date: Intl Filing Date March 12, 1997	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,925,922	May 15, 1990	Byers et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	EP 129 434	Sept. 6, 1989	EPO			
	EP 256 471	Feb. 24, 1988	EPO			
	WO 88/05309	July 28, 1988	PCT			
	WO 94/02016	Feb. 3, 1994	PCT			
	WO 91/09058	June 27, 1991	PCT			
	WO 95/34817	Dec. 21, 1995	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	1989	Abstract of Accession no. 90658782 Cancerlit, "Fourth International Conference on Monoclonal Antibody Immunocjugates for Cancer", March 30 to April 1, 1989, San Diego, CA, UCSD Cancer Center.				
	1992	Abstract of Crews J.R. et al.; <i>Int. Journ. of cancer</i> , July 9, 1992; Vol. 51, no. 2.				
	1994	Dialog Information Service, File 159, Cancerlit, Dialog accession no. 01046200, Cancerlit accession no. 94290389, Lemoli RM et al: "Positive selection of hematopoietic CD34+ stem cells provides 'indirect purging' of CD34- lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins", <i>Bone Marrow Transplant</i> , 13(4):465-71, 1994.				
	1994	Dialog Information Service, File 159, Cancerlit, Dialog accession no. 01018250, Cancerlit accession no. 94084695, Myklebust AT et al: "Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow", <i>Cancer Res</i> , 54(1):209-14, 1994.				
	1991	Dialog Information Service, File 159, Cancerlit, Dialog accession no. 00803246, Cancerlit accession no. 91348943, Tecce R. et al: "Production and Characterization of two Immunotoxins Specific for MSB An11 Leukemia", <i>Int J. Cancer</i> 49(2):310-6, 1991.				
	1986	Dialog Information Service, File 159, Cancerlit, Dialog accession no. 00447849, Cancerlit accession no. 86110672, Tenevitsky AG et al: "Elimination of Murine Erythroleukemic Stem Cells with a Novel Anti-Erythroid Antibody Conjugated to Ricin a-chain: A Model for Studies of Bone-Marrow Transplantation Therapy", <i>Int. J. Cancer</i> , 37(2):263-73, 1986.				
	1996	Dialog Information Service, File 159, Cancerlit, Dialog accession no. 01268628, Cancerlit accession no. 97051812, Kvalheim G. et al: "Purging of tumor cells from leukapheresis products: experimental and clinical aspects", <i>J. Hematother</i> , 5(4):427-36, 1996.				

RECEIVED
CENTRAL FAX CENTER
JAN 26 2005

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1448)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Sheet 2 of 2

Date Mailed: October 30, 1998

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,751
	Applicant: FODSTAD et al.	
	Filing Date: Intl Filing Date March 12, 1997	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	1986	Michael J. Bjorn, et al.; "Antibody-Pseudomonas Exotoxin A Conjugates Cytotoxic to Human Breast Cancer Cells in Vitro"; <i>Cancer Research</i> , July 1986; pp. 3262-3267.				
	1989	Im c. Anderson, et al.; "Elimination of Malignant Clonogenic Breast Cancer Cells from Human Bone Marrow"; <i>Cancer Research</i> ; pp. 4659-4664.				
	1991	K.C. O-Briant, MS, et al.; "Elimination of Clonogenic Breast Cancer Cells from Human Bone Marrow"; <i>Cancer</i> , 1991; pp. 1272-1278.				
	1993	C.L. Tyer, et al.; "Breast Cancer Cells are Effectively Purged from Peripheral Blood Progenitor cells Using an Immunomagnetic Technique"; Abstract to First meeting of International Society for Hematotherapy and Graft Engineering, Orlando, FL, 1993.				
	1992	Fiorenzo Stirpe, et al.; "Ribosome-Inactivating Proteins from Plants: Present Status and future Prospects"; <i>BioTechnology</i> , April 1992; Vol. 10, pp. 405-412.				
	1993	Luigi Barbieri, et al.; "Ribosome-inactivating proteins from plants"; <i>Biochimica et Biophysica Acta</i> , 1993; pp. 237-282.				
	1994	R.M. Lermoli, et al.; "Positive selection of hematopoietic CD34+ stem cells provides 'indirect purging' of CD34- lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins"; <i>Bone Marrow Transplantation</i> , 1994; pp. 465-471.				
	1992	I.J. Diel, et al.; "Detection of Tumor Cells in Bone Marrow of Patients with Primary Breast Cancer: A Prognostic Factor for Distant Metastasis"; <i>Journal of Clinical Oncology</i> , 1992; pp. 1534-1539.				
	1993	Arne T. Muklebust, et al.; "Eradication of Small Cell Lung Cancer Cells from Human Bone Marrow with Immunotoxins"; <i>Cancer Research</i> , 1993; pp. 3784-3788.				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 30, 1998

Sheet 1 of 2

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,751
	Applicant: FODSTAD et al.	
	Filing Date: Intl. Filing Date March 12, 1997	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,322,678	Jun. 21, 1994	Morgan, Jr. et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	1993	William P. Peters, et al.; "High-Dose Chemotherapy and Autologous Bone Marrow Support as Consolidation After Standard-Dose Adjuvant Therapy for High-Risk Primary Breast Cancer"; <i>Journal of Clinical Oncology</i> ; June 1993; Vol. 11, No. 6, pp.1132-1143.				
	1994	James O. Armitage, M.D.; "Bone Marrow Transplantation"; <i>New England Journal of Medicine</i> ; March 24, 1994; Vol. 330, No. 12, pp. 827-838.				
	1990	Thomas J. Moss, et al.; "Contamination of Peripheral Blood Stem Cell Harvests by Circulating Neuroblastoma Cells"; <i>Blood</i> ; 1990; Vol. 76, No. 9, pp. 1879-1883.				
	1993	Amy A. Ross, et al.; "Detection and Viability of Tumor Cells in Peripheral Blood Stem Cell Collections From Breast Cancer Patients Using Immunocytochemical and clonogenic Assay Techniques"; <i>Blood</i> ; 1993; Vol. 82, No. 9, pp. 2605-2610.				
	1993	Malcolm K. Brenner, et al.; "Gene-marking to trace origin of relapse after autologous bone-marrow transplantation"; <i>Lancet</i> ; 1993; pp. 85-86.				
	1991	John G. Grivven, M.D., et al.; "Immunologic Purging of Marrow Assessed by PCR Before Autologous Bone Marrow Transplantation for B-Cell Lymphoma"; <i>New England Journal of Medicine</i> ; November 28, 1991; Vol. 325, No. 22, pp. 1525-1533.				
	1994	Elizabeth J. Shpall, et al.; "Release of Tumor Cells from Bone Marrow"; <i>Blood</i> ; February 1, 1994; pp. 623-625.				
	1994	Wolfram Brugger, et al.; "Mobilization of Tumor Cells and Hematopoietic Progenitor Cells Into Peripheral Blood of Patients With Solid Tumors"; <i>Blood</i> ; 1994; Vol. 83, No. 3, pp. 636-640.				
	1992	Ger J. Strous, et al.; "Mucin-Type Glycoproteins"; <i>Critical Reviews in Biochemistry and Molecular Biology</i> ; 1992; pp. 57-92.				
	1986	Lou de Leij, et al.; "The Use of Monoclonal Antibodies for the Pathological Diagnosis of Lung Cancer"; In: H.H. Hansen (ed), <i>Lung Cancer: Basic and Clinical Aspects</i> ; Boston: Martinus Nijhoff Publishers, 1986; pp. 31-48.				
	1992	Aslak Godal, et al.; "Immunotoxins directed Against the High-Molecular-Weight Melanoma-Associated Antigen. Identification of Potent Antibody-Toxin Combinations"; <i>Int. J. Cancer</i> ; 1992; pp. 631-635.				
	1978	V.D. Courtenay, et al.; "An In Vitro Colony Assay For Human Tumours Grown in Immune-Suppressed Mice and Treated In Vivo with Cytotoxic Agents"; <i>Br. J. Cancer</i> ; 1978; pp. 261-268.				
	1992	M.Y. Wang, et al.; "An effective immunomagnetic method for bone marrow purging in T cell malignancies"; <i>Bone Marrow Transplantation</i> ; 1992; pp. 319-323.				
	1994	Anne T. Myklebust, et al.; "Comparison of Two Antibody-based Methods for Elimination of Breast Cancer Cells from Human Bone Marrow"; <i>Cancer Research</i> ; 1994; pp. 209-214.				
	1993	Connie J. Eaves; "Peripheral Blood Stem Cells Reach New Heights"; <i>Blood</i> ; 1993; pp. 1957-1959.				
	1994	Elizabeth J. Shpall, et al.; "Transplantation of Enriched CD34-Positive Autologous Marrow Into Breast Cancer Patients Following High-Dose Chemotherapy: Influence of CD34-Positive Peripheral-Blood Progenitors and Growth Factors on Engraftment"; <i>Journal of Clinical Oncology</i> ; 1994; Vol. 12, No. 1, pp. 28-36.				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1448)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: December 3, 1998

Sheet 1 of 1

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,751
	Applicant: FODSTAD, et al.	
	Filing Date: Int Filing Date March 12, 1997	Group Art Unit: Unknown

[illegible]

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 12, 1999

Sheet 1 of 3

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,731
	Applicant: FODSTAD, et al.	
	Filing Date: October 30, 1998	Group Art Unit: 1643

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,095,097	Mar. 10, 1992	Hermertin et al.			
	5,536,644	Jul. 16, 1996	Ullman et al.			
	5,374,531	Dec. 20, 1994	Jensen			
	5,256,532	Oct. 26, 1993	Melnicoff et al.			
	5,264,344	Nov. 23, 1993	Sneath			
	5,424,213	Jun. 13, 1995	Mougin			
	5,491,068	Feb. 13, 1996	Benjamin et al.			
	5,514,340	May 7, 1996	Lansdorp et al.			
	5,624,815	Apr. 29, 1997	Grant et al.			
	4,857,452	Aug. 15, 1989	Ho			
	4,752,569	Jun. 21, 1988	Terasaki et al.			
	5,019,497	May 28, 1991	Olsson			
	4,659,678	Apr. 21, 1987	Forrest et al.			
	5,422,277	Jun. 6, 1995	Connelly et al.			
	4,219,411	Aug. 26, 1980	Yen et al.			
	4,710,472	Dec. 1, 1987	Saur et al.			
	4,920,061	apr. 24, 1990	Poynton et al.			
	4,510,244	Apr. 9, 1985	Parks et al.			
	5,340,719	Aug. 23, 1994	Hajek et al.			
	5,326,696	Jul. 5, 1994	Chang			
	5,405,784	Apr. 11, 1995	Van Hoegaerden			
	5,219,763	Jun. 15, 1993	Van Hoegaerden			
	5,194,300	Mar. 16, 1993	Cheung			
	5,290,707	Mar. 1, 1994	Wood			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	016 552	Oct. 1, 1980	EPO			
	395 355	Oct. 31, 1990	EPO			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 12, 1999

Sheet 2 of 3

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,751
	Applicant: FODSTAD, et al.	
	Filing Date: October 30, 1998	Group Art Unit: 1643

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	WO 90/07380	Jul. 12, 1990	PCT			
	WO 90/10692	Sep. 20, 1990	PCT			
	WO 91/15766	Oct. 17, 1991	PCT			
	95/24648	Sep. 14, 1995	PCT			
	WO A1 94/07139	Mar. 31, 1994	PCT			
	94/07138	Mar. 31, 1994	PCT			
	098 534	Jan. 18, 1984	EPO			
	339 769	Nov. 2, 1989	EPO			
	131 934	Jan. 23, 1985	EPO			
	WO 91/01368	Feb. 7, 1991	PCT			
	WO 92/04961	Apr. 2, 1992	PCT			
	WO 91/09938	Jul. 11, 1991	PCT			
	403960	Jun. 14, 1990	EPO			
	241 042	Oct. 14, 1987	EPO			
	WO 94/07142	Mar. 31, 1994	PCT			
	2638849	May 11, 1990	France			
	3811566	Oct. 27, 1988	Germany			
	537 827	Apr. 21, 1993	EPO			
	WO 96/31777	Oct. 10, 1996	PCT			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 12, 1999

Sheet 3 of 3

PTO 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 89/125,751
	Applicant: FODSTAD, et al.	
	Filing Date: October 30, 1998	Group Art Unit:

OTHER DOCUMENTS (Including Author, Title/Data, Pertinent Pages, Etc.)		
1989	D. Pilling, et al., "Time kinetics of interaction between lymphocytes and magnetic polymer particles", <i>National Library of Medicine, File Medline, Medline accession no. 90010165</i> ; Sept. 1, 1989; 124(2) pp. 235-41.	
1991	R.M. Leven, et al., "Immunomagnetic bead isolation of megakaryocytes from guinea-pig bone marrow: effect of recombinant interleukin-6 on size, ploidy and cytoplasmic segmentation", <i>National Library of Medicine, File Medline, Medline accession no. 07671620</i> ; Br J Haematol Mar 1991; 77 (3), pp. 267-273.	
January 1993	BIO/TECHNOLOGY, Volume 11, Bjorn-Ivar Haulenes et al., "Application of Magnetic Beads in Bioassays" page 60.	
1990	SCAND J IMMUNOL, Volume 31, J. Heldrup, "A New Technique Using Aggregating Antibody Against Glycophorin-A for Purifying Ficoll-Paque-Separated Leucocytes of Contaminating Erythrocytes", page 289 - page 296, see "Materials and methods" and page 295, right column.	
1997	Rye, et al., "Immunobead Filtration", <i>American Journal of Pathology</i> , January 1997; Vol. 150, No. 1, pp. 99-107.	
1993	A. Benrick et al., "A Rapid Method for Selecting Specific T-Heloma Clones using Paramagnetic Dynabeads", <i>Scand. J. Immunol.</i> ; 1993; pp. 212-214.	
1989	Hiroshi Maeda, "Applicability of an Immunomagnetic Bead Technique for a Forensic Identification of ABO Blood Types: The Use of Fluorescent Microspheres", <i>Am J Legal Med</i> ; 1989; 322-327.	
1996	Andrew J. Gorvis, et al., "Detection of Cell Surface Antigens Using Antibody-Conjugated Fluorosphers (ACF): Application for Six-Color Immunofluorescence", <i>Biotechnology</i> ; 1996; 14: 508-503.	
	Derwent accession no. 93-173192, 7885.55 US WO 93/0421, DW9321 KK: "Sensitivity detection of ligand-receptor reaction by combining fluorescent fine particles with objective substance, passing mixt. through flow cytometer, counting number of agglomerates etc."; & JPA, 5107249.	
1985	K.A. Mairhead, et al., "Flow Cytometry: Present and Future", <i>Biotechnology</i> , April 1985; Vol. 3, pp. 337-356	
1992	W. Kemmer, et al., "Separation of tumor cells from a suspension of dissociated human colorectal carcinoma tissue by means of monoclonal antibody-coated magnetic beads", <i>Journal of Immunological Methods</i> ; 1992; pp. 197-200.	
1990	C.I. Civra, et al., "positive stem cell selection - basic science", <i>Progress in Clinical and Biological Research</i> ; Vol. 333, 1990; pp. 383-402.	
1984	B.H. Dunlop, et al., "Magnetic separation in biotechnology", <i>Biotech ADVS</i> ; Vol. 2, 1984, pp. 66-69.	
1985	C.H. Seitchell, "Magnetic Separations in Biotechnology - a Review", <i>J. Chem. Tech. Biotechnol.</i> ; Vol. 35B, No. 3, 1985, pp. 175-182.	
1991	J.H. Pizzonia, et al., "Immunomagnetic separation, primary culture, and characterization of cortical thick ascending limb plus distal convoluted tubule cells from mouse kidney", <i>National Library of Medicine, File Medline, Medline accession no. 07671620</i> ; Br J Haematol Mar 1991; 77 (3), pp. 267-273.	
1987	O. Kvalheim, et al., "Elimination of B-1 lymphoma Cells from Human Bone Marrow: Model Experiments Using Monodisperse Magnetic Particles Coated with Primary Monoclonal Antibodies", <i>Cancer Research</i> ; Vol. 47, February 1987, pp. 846-851.	
1987	J.T. Keimhead, et al., "Monoclonal antibodies and magnetic microspheres for the depletion of leukemic cells from bone marrow harvested for autologous transplantation", <i>Bone Marrow Transplantation</i> ; 1987; Vol. 2, pp. 133-139.	
1987	G. Kvalheim, et al., "Immunomagnetic purging of B-lymphoma cells from human bone marrow", <i>Dialog Information service. File 159, Cancer</i> ; Dialog accession no. 00559663; Fourth European Conference on Clinical Oncology and Cancer Nursing, Nov. 1-4, 1987, Madrid, Federation of European Cancer Societies, pp. 262, 1987.	
1988	T. Lea, et al., "Monodisperse magnetic polymer particles: their use in separation of cells and subcellular components, and in the study of lymphocyte function in vivo", <i>National Library of Medicine, File Medline, Medline accession no. 90234499</i> ; J. Mol. Recognit.; Feb. 1988; 1(1), pp. 9-18.	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent & Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: October 5, 2004

Sheet 1 of 2

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,751
	Applicant: FODSTAD et al.	
	Filing Date: October 30, 1998	Group Art Unit: 1642

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		"Making the most of mucin: a novel target for tumor immunotherapy", Barratt-Boyes SM, Cancer Immunol Immunother. 1996 Nov; 43(3): 142-51.					
		"The Epithelial Glycoprotein 2 (EGP-2) Promoter-driven Epithelial-specific Expression of EGP-2 in Transgenic Mice: A New Model to Study Carcinoma-directed Immunotherapy", McLaughlin et al., Cancer Research 61, 4105-4111, May 15, 2001.					
		"Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy", Winthrop et al., Clinical Cancer Research, Vol. 9, 3845s-3853s, September 1, 2003 (Suppl.).					
		"Kinetics of Uptake and Degradation of an Abrin Immunotoxin by Melanoma Cells and Studies of the Rates of Cellular Intoxication", Godal et al., Int. J. Cancer: 42, 400-404 (1988).					
		"Studies on the Mechanism of Action of Abrin-9.2.27 Immunotoxin in Human Melanoma Cell Lines", Godal et al., Cancer Research 47, 6243-6247, December 1, 1987.					
		"Systematic Immunotoxin Treatment Inhibits Formation of Human Breast Cancer Metastasis and Tumor Growth in Nude Rats", Engebraaten et al., Int. J. Cancer: 88, 970-976 (2000).					
		"A Murine cDNA Encodes a Pan-Epithelial Glycoprotein that is also Expressed on Plasma Cells", Bergsagel et al., The Journal of Immunology, Vol. 148, 590-596, No. 2, January 15, 1992.					
		"Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2", Szala et al., Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 3542-3546, May 1990 Biochemistry.					
		"Molecular Cloning and Characterization of a Human Adenocarcinoma/Epithelial Cell Surface Antigen Complementary DNA", Strnad et al., Cancer Research 49, 314-317, January 15, 1989.					
		Appendix 3-6, "Monoklonaler Antikörper BM7" and Appendix 3-7, "Monoklonaler Antikörper BM2", Brummend et al., Cancer Research, 1994, 54: 4162-4168					
		"Pharmacokinetics and Scintigraphy of Indium-111-DTPA-MOC-31 in Small-Cell Lung Carcinoma", Kosterink et al., The Journal of Nuclear Medicine- Vol. 36, No. 12, December 1995.					
		"Can therapeutic concentrations of the anti EGP2 immunotoxin conjugate MOC31-PE be achieved in patients with antigen positive carcinomas? A phase I study in patients with advanced mammary, lung, colorectal or prostate carcinoma", Aamdal et al., pp. 1-24.					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE